Astrazeneca AB has divulged proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin ligase cereblon unit coupled to an androgen receptor (AR) targeting moiety via a linker acting as AR degradation inducers reported to be useful for the treatment of cancer.
Researchers from Imperial College London presented data from a study that aimed to assess the role of miR-1271-5p in prostate cancer (PCa) progression.
Researchers from Sensei Biotherapeutics Inc. presented preclinical data for the novel CD28xVISTA bispecific antibody (BsAb), SNS-201, being developed for the treatment of prostate cancer.
The University of California and the US Department of Veterans Affairs have patented androgen receptor (AR) antagonists reported to be useful for the treatment of prostate cancer.
The TRPV6 calcium channel is overexpressed in several types of cancer deriving from epithelia where calcium control is unbalanced, such as prostate, colon or breast cancer, among others.
Nextpoint Therapeutics Inc. has unveiled NPX-372, a novel T-cell engager for solid tumors. NPX-372 is a CD3 bispecific antibody with unique capabilities to redirect T cell-mediated cytotoxicity toward B7-H7-positive tumors such as colorectal carcinoma, non-small-cell lung cancer, renal cell carcinoma and prostate cancer.
Researchers developed a new method using light to analyze crystals in dry blood samples to detect prostate cancer early. The scientists employed a polarization-based image reconstruction technique which demonstrated an accuracy rate of more than 90% in both the early diagnosis and classification of cancer.
Grail Inc.’s multi-cancer early detection test, Galleri, preferentially screens for aggressive prostate cancer, addressing concerns about overdiagnosis and subsequent overtreatment of indolent cancers, a study published in JCO Precision Oncology demonstrated.
The mechanisms contributing to prostate cancer progression are still incompletely understood. There has been increasing attention on myosin heavy chain 6 (MYH6) for its involvement in cellular processes beyond the heart.
Serine/threonine-protein kinase PLK4 (Polo-like kinase 4) has emerged as an attractive therapeutic target in prostate cancer, since it plays crucial roles in cell cycle regulation and tumor progression. Investigators from 2nd Affiliated Hospital of Wenzhou Medical University have prepared and tested the PLK4 inhibitor NL-13 for the potential treatment of prostate cancer.
